

Ana-Maria Orbai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1746463/publications.pdf>

Version: 2024-02-01

91
papers

6,963
citations

257101

24
h-index

62479

80
g-index

98
all docs

98
docs citations

98
times ranked

7838
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. Arthritis Care and Research, 2022, 74, 588-597.	1.5	17
2	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. Clinical Infectious Diseases, 2022, 74, 427-436.	2.9	15
3	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2022, , jrheum.211322.	1.0	1
4	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. Joint Bone Spine, 2022, , 105372.	0.8	3
5	Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. Journal of Rheumatology, 2022, 49, 894-902.	1.0	7
6	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. RMD Open, 2022, 8, e002031.	1.8	4
7	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. Arthritis Care and Research, 2021, 73, 593-602.	1.5	12
8	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 58-66.	1.0	5
9	Reply. Arthritis and Rheumatology, 2021, 73, 175-176.	2.9	0
10	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatology and Therapy, 2021, 8, 199-217.	1.1	8
11	Reply. Arthritis and Rheumatology, 2021, 73, 357-358.	2.9	0
12	A Novel Qualitative Study Assessing Patient-Reported Outcome Measures Among People Living with Psoriatic Arthritis or Ankylosing Spondylitis. Rheumatology and Therapy, 2021, 8, 609-620.	1.1	7
13	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. Rheumatology, 2021, 60, 5292-5299.	0.9	4
14	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2021, , jrheum.201679.	1.0	2
15	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 367-386.	1.6	2
16	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1547-1551.	1.0	3
17	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3
18	OPO298...ARE PATIENTS WITH PSORIATIC ARTHRITIS BEING TREATED OPTIMALLY ACROSS THE WORLD? DISPARITIES IN HEALTH CARE FOR PATIENTS WITH PSORIATIC ARTHRITIS ACROSS COUNTRIES WITH DIFFERENT GDP'S, AN ANALYSIS OF 429 PATIENTS FROM 13 COUNTRIES. Annals of the Rheumatic Diseases, 2021, 80, 183-183.	0.5	0

#	ARTICLE	IF	CITATIONS
19	POS1020â€¦EFFICACY OF TOFACITINIB ON DACTYLITIS IN INDIVIDUAL DIGITS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 777.2-778.	0.5	1
20	POS1050â€¦SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 802-803.	0.5	0
21	POS1029â€¦GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 785-786.	0.5	0
22	Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USAâ€”a retrospective study of claims data from 2009 TO 2020. <i>Clinical Rheumatology</i> , 2021, 40, 4933-4942.	1.0	12
23	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 1223-1240.	1.1	6
24	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	1.6	4
25	Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naïve and TNF-inadequate responder patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 329-336.	0.4	2
26	Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6975-6991.	1.6	6
27	Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naïve and TNF-inadequate responder patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 329-336.	0.4	3
28	Content validity of psoriatic arthritis composite indices: anchoring with the patient perspective and the core domain set. <i>Rheumatology</i> , 2020, 59, 1-4.	0.9	6
29	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). <i>Rheumatology</i> , 2020, 59, 1495-1504.	0.9	18
30	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	1.0	10
31	Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and Neutrophils. <i>Arthritis and Rheumatology</i> , 2020, 72, 557-564.	2.9	30
32	Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 109-117.	3.3	6
33	Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. <i>Rheumatology</i> , 2020, 59, 1662-1670.	0.9	42
34	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	1.5	39
35	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.3	7
36	Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey. <i>Rheumatology and Therapy</i> , 2020, 7, 937-948.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	1.6	6
38	Measurement of minimal disease activity in psoriatic arthritis using PROMISâ€Physical Function or the Health Assessment Questionnaireâ€Disability Index. <i>Arthritis Care and Research</i> , 2020, , .	1.5	2
39	Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps. <i>BMC Rheumatology</i> , 2020, 4, 32.	0.6	18
40	Treatment Continuation Guidance in Psoriatic Arthritis Clinical Care. <i>Journal of Rheumatology</i> , 2020, 47, 1600-1602.	1.0	0
41	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , 2020, 93, 100601.	0.5	10
42	Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. <i>RMD Open</i> , 2020, 6, e000928.	1.8	31
43	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	0.8	14
44	FRI0357â€...IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 775.1-775.	0.5	1
45	AB0794â€...CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FLNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1696.2-1697.	0.5	0
46	AB0814â€...SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY WITH IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS: 3-YEAR RESULTS FROM SPIRIT-P2 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1709-1710.	0.5	0
47	<p>Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 97-107.	1.2	16
48	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 38.	1.6	38
49	Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1374-1378.	1.0	6
50	Investigating Dimensions of Stiffness in Rheumatoid and Psoriatic Arthritis: The Australian Rheumatology Association Database Registry and OMERACT Collaboration. <i>Journal of Rheumatology</i> , 2019, 46, 1462-1469.	1.0	4
51	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	1.0	36
52	SAT0367â€...PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. , 2019, , .		0
53	SAT0369â€...SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR. , 2019, , .		0
54	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	1.0	43

#	ARTICLE	IF	CITATIONS
55	Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 46, 266-273.	1.0	9
56	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.5	59
57	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
58	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	1.5	264
59	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	1.0	14
60	Towards improving measurement of stiffness in rheumatology. <i>Rheumatology</i> , 2018, 57, 206-208.	0.9	0
61	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.5	16
62	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	1.6	50
63	Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. <i>RMD Open</i> , 2018, 4, e000692.	1.8	17
64	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	1.2	20
65	Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. <i>Quality of Life Research</i> , 2018, 27, 2443-2451.	1.5	17
66	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. <i>BMC Rheumatology</i> , 2018, 2, 24.	0.6	24
67	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	1.0	10
68	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	1.0	93
69	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.5	194
70	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	1.0	42
71	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1904-1910.	1.0	11
72	A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1445-1452.	1.0	17

#	ARTICLE	IF	CITATIONS
73	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open, 2016, 2, e000217.	1.8	35
74	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 965-969.	1.0	24
75	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 970-973.	1.0	6
76	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	2.9	726
77	Patient-Reported Outcomes in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2016, 42, 265-283.	0.8	46
78	More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions. Journal of Rheumatology, 2015, 42, 2182-2184.	1.0	19
79	Enhanced Patient Involvement and the Need to Revise the Core Set Report from the Psoriatic Arthritis Working Group at OMERACT 2014. Journal of Rheumatology, 2015, 42, 2198-2203.	1.0	34
80	Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials. Current Rheumatology Reports, 2015, 17, 28.	2.1	60
81	Targeting extra-articular manifestations in PsA. Current Opinion in Rheumatology, 2015, 27, 111-117.	2.0	31
82	Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0138543.	1.1	164
83	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1206-1211.	1.0	13
84	Brief Report: Antisynthetase Syndrome Associated Myocarditis. Journal of Cardiac Failure, 2014, 20, 939-945.	0.7	24
85	Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2290-2294.	1.0	48
86	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. Journal of Rheumatology, 2014, 41, 799-809.	1.0	65
87	Stiffness Has Different Meanings, I Think, to Everyone: Examining Stiffness From the Perspective of People Living With Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 1662-1672.	1.5	32
88	A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies. Medicine (United States), 2012, 91, 220-228.	0.4	74
89	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
90	The effectiveness of tricyclic antidepressants on lumbar spinal stenosis. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 22-4.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. Patient, O, , .	1.1	3